SCOPUS 정보 검색 플랫폼

OncoImmunology

Volumn 1, Issue 2, 2012, Pages 258-259

Modulation of DNA repair genes induced by TLR9 agonists: A strategy to eliminate "altered" cells?

(4) Sommariva, Michele a,b De Cecco, Loris b Tagliabue, Elda b Balsari, Andrea a,b

a UNIVERSITY OF MILAN (Italy)

b NATIONAL CANCER INSTITUTE (Italy)

Author keywords

Altered cells; Chemotherapy; DNA repair; Immune cell; Ovarian cancer; Toll like receptor 9

Indexed keywords

ANTHRACYCLINE; CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; TOLL LIKE RECEPTOR 9;

APOPTOSIS; BREAST CANCER; CANCER CELL CULTURE; CELL INTERACTION; COLON CARCINOMA; DNA DAMAGE; DNA REPAIR; DRUG RESPONSE; GENE CONTROL; GENE EXPRESSION REGULATION; HUMAN; IMMUNOCOMPETENT CELL; INNATE IMMUNITY; LIFESPAN; NONHUMAN; NOTE; OVARY CANCER; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT;

EID: 84874612456 PISSN: 21624011 EISSN: 2162402X Source Type: Journal
DOI: 10.4161/onci.1.2.18343 Document Type: Note

Times cited : (6)

References (10)

1
- 79951648552
- Toll-like receptor 9 agonists as cancer therapeutics
- Holtick U, Scheulen ME, von Bergwelt-Baildon MS, Weihrauch MR. Toll-like receptor 9 agonists as cancer therapeutics. Expert Opin Investig Drugs 2011; 20: 361-72; http://dx.doi.org/10.1517/13543784.2011.553187
- (2011) Expert Opin Investig Drugs , vol.20 , pp. 361-372
- Holtick, U.¹ Scheulen, M.E.² von Bergwelt-Baildon, M.S.³ Weihrauch, M.R.⁴

2
- 11344265206
- Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy
- Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, et al. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res 2005; 11:361-9.
- (2005) Clin Cancer Res , vol.11 , pp. 361-369
- Mason, K.A.¹ Ariga, H.² Neal, R.³ Valdecanas, D.⁴ Hunter, N.⁵ Krieg, A.M.⁶

3
- 45349090044
- Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft
- Petrangolini G, Tortoreto M, Perego P, Carenini N, De Cesare M, Balsari A, et al. Combination of metronomic gimatecan and CpG-oligodeoxynucleotides against an orthotopic pancreatic cancer xenograft. Cancer Biol Ther 2008; 7:596-601; http://dx.doi.org/10.4161/cbt.7.4.5548
- (2008) Cancer Biol Ther , vol.7 , pp. 596-601
- Petrangolini, G.¹ Tortoreto, M.² Perego, P.³ Carenini, N.⁴ De Cesare, M.⁵ Balsari, A.⁶

4
- 0042024964
- CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma
- Weigel BJ, Rodeberg DA, Krieg AM, Blazar BR. CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. Clin Cancer Res 2003; 9:3105-14; PMID:12912962
- (2003) Clin Cancer Res , vol.9 , pp. 3105-3114
- Weigel, B.J.¹ Rodeberg, D.A.² Krieg, A.M.³ Blazar, B.R.⁴

5
- 80054048790
- TLR9-agonists oppositely modulate DNA-repair genes in tumor versus immune cells and enhance chemotherapy effects
- Sommariva M, De Cecco L, De Cesare M, Sfondrini L, Ménard S, Melani C, et al. TLR9-agonists oppositely modulate DNA-repair genes in tumor versus immune cells and enhance chemotherapy effects. Cancer Res 2011; 20:6382-90.
- (2011) Cancer Res , vol.20 , pp. 6382-6390
- Sommariva, M.¹ De Cecco, L.² De Cesare, M.³ Sfondrini, L.⁴ Ménard, S.⁵ Melani, C.⁶

6
- 31144459985
- Oncogenic pathway signatures in human cancers as a guide to targeted therapies
- Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, et al. Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature 2006; 439:353-7; http://dx.doi.org/10.1038/nature04296
- (2006) Nature , vol.439 , pp. 353-357
- Bild, A.H.¹ Yao, G.² Chang, J.T.³ Wang, Q.⁴ Potti, A.⁵ Chasse, D.⁶

7
- 0037137519
- A gene-expression signature as a predictor of survival in breast cancer
- van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009; http://dx.doi.org/10.1056/NEJMoa021967
- (2002) N Engl J Med , vol.347 , pp. 1999-2009
- van de Vijver, M.J.¹ He, Y.D.² van't Veer, L.J.³ Dai, H.⁴ Hart, A.A.⁵ Voskuil, D.W.⁶

8
- 73349142317
- Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice
- Westwood JA, Haynes NM, Sharkey J, McLaughlin N, Pegram HJ, Schwendener RA, et al. Toll-Like Receptor Triggering and T-Cell Costimulation Induce Potent Antitumor Immunity in Mice. Clin Cancer Res 2009; 15:7624-33; http://dx.doi.org/10.1158/1078-0432.CCR-09-2201
- (2009) Clin Cancer Res , vol.15 , pp. 7624-7633
- Westwood, J.A.¹ Haynes, N.M.² Sharkey, J.³ McLaughlin, N.⁴ Pegram, H.J.⁵ Schwendener, R.A.⁶

9
- 65549140232
- Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo
- Klaschik S, Tross D, Klinman DM. Inductive and suppressive networks regulate TLR9-dependent gene expression in vivo. J Leukoc Biol 2009; 85: 788-95; http://dx.doi.org/10.1189/jlb.1008671
- (2009) J Leukoc Biol , vol.85 , pp. 788-795
- Klaschik, S.¹ Tross, D.² Klinman, D.M.³

10
- 53049108931
- Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy
- De Cesare M, Calcaterra C, Pratesi G, Gatti L, Zunino F, Ménard S, et al. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy. Clin Cancer Res 2008; 14:5512-8; http://dx.doi.org/10.1158/1078-0432.CCR-08-0445
- (2008) Clin Cancer Res , vol.14 , pp. 5512-5518
- De Cesare, M.¹ Calcaterra, C.² Pratesi, G.³ Gatti, L.⁴ Zunino, F.⁵ Ménard, S.⁶

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.